Skip to main content

Rheumatoid Arthritis

      RT @RichardPAConway: Krijbolder et al. TREAT EARLIER DBRCT. MTX vs PBO for pre-RA. Treat 1 year, stop, and follow 1 year
      Krijbolder et al. TREAT EARLIER DBRCT. MTX vs PBO for pre-RA. Treat 1 year, stop, and follow 1 year. No difference in RA development. Delay in ACPA+ or high risk. Sustained benefit in MTX group on pain, EMS, function, MRI. @RheumNow #ACR22 Abstr#1603 https://t.co/M2qQfgrhC1 https://t.co/UUeknTLx0K
      RT @drdavidliew: Does curcurmin (tumeric) do anything in RA?
      Big talk & sales.

      Best chance would be keeping pts in
      2 years ago
      Does curcurmin (tumeric) do anything in RA? Big talk & sales. Best chance would be keeping pts in remission during csDMARD taper: DBRCT n=200 52w, high bioavail form, good serum conc Absolutely nothing vs placebo I'll call it: just doesn't work in RA ABST1587 #ACR22 @RheumNow https://t.co/wecEfkXT55
      RT @Yuz6Yusof: #ACR22 Abstr#1756 More data on safety of #COVID vaccine to cite when counselling patients with inflammato
      #ACR22 Abstr#1756 More data on safety of #COVID vaccine to cite when counselling patients with inflammatory arthritis (IA). Data from COVAX registry (over 7000 pts) showed rates of serious adverse event was low 0.3% vs 2.5% in those with non-IA RMD group @RheumNow https://t.co/iucDK1GpU4
      RT @RichardPAConway: Deane et al STOP RA trial. DBRCT HCQ vs PBO pre-RA. Treat 1 year, stop, 2 year follow up. Does not
      Deane et al STOP RA trial. DBRCT HCQ vs PBO pre-RA. Treat 1 year, stop, 2 year follow up. Does not prevent RA development. Literally no effect at all, even during treatment phase. @RheumNow #ACR22 Abstr#1604 https://t.co/7jHv7cs5DT https://t.co/GNblKs90RU
      RT @Janetbirdope: Preventing #rheumatoid #arthritis - the holy grail! STOPRA RCT of strong ACPA+; CCP3 high titre. No i
      2 years ago
      Preventing #rheumatoid #arthritis - the holy grail! STOPRA RCT of strong ACPA+; CCP3 high titre. No inflammatory arthritis. RCT of #Hydroxychloroquine vs placebo, N=142 Pts. At 3 yrs NO DIFF in onset@of RA in each group. identical curves. Abst1604 #ACR22 #ACRBest @RheumNow Darn! https://t.co/bEgbkxGSR4
      RT @uptoTate: Abs 1417 finds physicians prefer ABA over TNFi for RF/ACPA+ pts w/ higher disease severity, older age, the
      Abs 1417 finds physicians prefer ABA over TNFi for RF/ACPA+ pts w/ higher disease severity, older age, the presence of extra-articular manifestations, and comorbidities such as heart failure. My question: Trouble getting it first line? #ACR22 @RheumNow https://t.co/tlFMgjgDNM https://t.co/ukoeLgSSUd